Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CCK(A), BUT NOT CCK(B), AGONISTS SUPPRESS THE HYPERLOCOMOTION INDUCEDBY ENDOGENOUS ENKEPHALINS, PROTECTED FROM ENZYMATIC DEGRADATION BY SYSTEMIC RB-101
Autore:
DAUGE V; CORRINGER PJ; ROQUES BP;
Indirizzi:
UNIV PARIS 05,UFR SCI PHARMACEUT & BIOL,CNRS,URA D1500,INSERM,U266 F-75270 PARIS 06 FRANCE
Titolo Testata:
Pharmacology, biochemistry and behavior
fascicolo: 2, volume: 50, anno: 1995,
pagine: 133 - 139
SICI:
0091-3057(1995)50:2<133:CBNCAS>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSTERIOR NUCLEUS-ACCUMBENS; DELTA-OPIOID RECEPTORS; DEGRADING-ENZYMES; BETA-ENDORPHIN; CHOLECYSTOKININ OCTAPEPTIDE; ANTAGONIST L-365,260; RAT-BRAIN; MORPHINE; STIMULATION; INHIBITOR;
Keywords:
CCKA AND CCKB AGONISTS; INHIBITOR OF ENKEPHALIN DEGRADATION; LOCOMOTOR ACTIVITY; INTERACTIONS BETWEEN CCK AND ENKEPHALINS; MICE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
52
Recensione:
Indirizzi per estratti:
Citazione:
V. Dauge et al., "CCK(A), BUT NOT CCK(B), AGONISTS SUPPRESS THE HYPERLOCOMOTION INDUCEDBY ENDOGENOUS ENKEPHALINS, PROTECTED FROM ENZYMATIC DEGRADATION BY SYSTEMIC RB-101", Pharmacology, biochemistry and behavior, 50(2), 1995, pp. 133-139

Abstract

Interactions between CCKergic and enkephalinergic systems were studied in mice using behavioral responses measured in Animex. The hyperlocomotion induced by 5 mg/kg of RE 101, a mixed inhibitor of enkephalin-degrading enzymes able to cross the blood-brain barrier, was previouslyshown to be mediated by delta-opioid receptor stimulation. The IP administration of a CCKA agonist, Boc-Tyr-Lys-(CONH-o-tolyl)-Asp-Phe NK2 (0.1, 1, 10 mu g/ kg), suppressed the hyperlocomotion produced by IV injection of 5 mg/kg of RE 101. The effect of the CCKA agonist was suppressed by a selective CCKA antagonist, devazepide, injected IP at doses of 20 and 200 mu g/kg and was potentiated by the selective delta-opioid antagonist naltrindole at the doses of 0.03 mg/kg. IP injection ofthe selective CCKB agonist BC 264 (0.1-1 mg/kg) did not modify the RE101-induced hyperlocomotor effect. These results reinforce the observed physiological antagonism between the endogenous CCK and opioid systems but are at variance with the responses measured in stressful conditions. It is concluded that CCKA, but not CCKB, receptor activation counteracts the opioid-related hyperlocomotion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 13:55:50